

WEBINAR

RESILIENCE AND RESERVE:
DEFINING, REFINING, AND
ADVANCING RESEARCH IN AGING

THURSDAY APRIL 30 2020
2-3 pm ET (11 am-12 pm PT)




RESEARCH CENTERS
COLLABORATIVE NETWORK
of the National Institute on Aging, NIH



A few housekeeping items...

- **All lines are muted**
- **Have a question?**

Enter in the Q&A box at the bottom of screen



- **Rolling—we will be recording...**

WEBINAR

RESILIENCE AND RESERVE:
DEFINING, REFINING, AND
ADVANCING RESEARCH IN AGING

THURSDAY APRIL 30 2020
2-3 pm ET (11 am-12 pm PT)



RESEARCH CENTERS
COLLABORATIVE NETWORK
of the National Institute on Aging, NIH



Jay Magaziner, PhD, MSHyg

Member,
RCCN Executive Committee

Director,
Center for Research on Aging,
University of Maryland.

Professor and Chair, Department of
Epidemiology and Public Health,
University of Maryland School of
Medicine; Baltimore, MD



**RESEARCH CENTERS
COLLABORATIVE NETWORK**
of the National Institute on Aging, NIH

The objective of the Research Centers Coordinating Network (RCCN) is to initiate new cross-disciplinary collaborative networks that bring together key thought leaders from each of the six NIA center programs to align approaches across programs that will uncover synergies and insights that lead to novel collaborations.

The RCCN is funded by the National Institute on Aging of the National Institutes of Health under Award Number U24AG058556. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The webinar will explore:

- **What is unique about the resilience paradigm**
- **What do we mean by resilience and reserve**
- **How is the NIA supporting programmatic developments in resilience and reserve**
- **Where to get started: directory of NIA resources**



Basil Eldadah, MD, PhD

Supervisory Medical Officer

Division of Geriatrics and Clinical Gerontology
(DGCG),
National Institute on Aging



Suzana Petanceska, PhD

Program Officer,

Division of Neuroscience,
National Institute on Aging



Giovanna Zappala, PhD, MD

Health Science Administrator,

Division of Geriatrics and Clinical Gerontology
(DGCG),
National Institute on Aging



Dana Plude, PhD

Deputy Director,

Division of Behavioral and Social Research
(DBSR),
National Institute on Aging

What's Unique About Resilience

Basil Eldadah, MD, PhD
Division of Geriatrics and Clinical Gerontology
NIA

RCCN Resilience Webinar
April 30, 2020



National Institute
on Aging


resilience (rē-zil'yens) [L. *resilio*, to spring back, rebound].

1. Energy (per unit of volume) released upon unloading.
2. Springiness or elasticity

Concepts invoked with resilience

- Responding to a stressor
- Bouncing back
- Resistance
- Recovery
- Adaptation
- Allostasis (maintaining homeostasis)
- Reserve
- Post-traumatic growth / thriving
- Hormesis

Resilience through the lens of the stress-response paradigm



The Question...

Resilient to what?

Resilient by which
outcome?

Is X resilient?

What predicts / is
associated with
X's resilience?

What makes X
resilient?

How do we get
somebody/something
like X to be resilient?


What is unique about the stress-response paradigm?

- Stressors and outcomes are identified


Stressors and outcome identified

STRESSOR; e.g.:

- Injury
- Toxin
- Infection
- Disease
- "Aging"
- Life event



*Physiologic/
Behavioral
Responses*



OUTCOME; e.g.:

- Survival
- Functional status
- Symptoms
- Indicators of health or disease
- Health-related quality of life
- Subjective well-being



Context
Chronicity
Multiplicity





MODERATORS



TIME

What is unique about the stress-response paradigm?

- Stressors and outcomes are identified
- Longitudinal with repeated measures



What is unique about the stress-response paradigm?

- Stressors and outcomes are identified
- Longitudinal with repeated measures
- **Person-centered**

The Question...

Resilient to what?

Resilient by which
outcome?

Is X resilient?

*Who/what
determines this??*


What predicts / is
associated with
X's resilience?

What makes X
resilient?

How do we get
somebody/something
like X to be resilient?

OUTCOME; e.g.:

- Survival
- Functional status
- Symptoms
- Indicators of health or disease
- Health-related quality of life
- Subjective well-being



What is unique about the stress-response paradigm?

- Stressors and outcomes are identified
- Longitudinal with repeated measures
- Person-centered
- Informs a unique class of interventions

Example interventions based on the stress-response paradigm

- Vaccination
- Exercise (“pre-habilitation”)
- Calorie / nutrient restriction
- Ischemia / hypoxia
- Heat / cold exposure

resilience (rē-zil'yens) [L. *resilio*, to spring back, rebound].

1. Energy (per unit of volume) released upon unloading.
2. Springiness or elasticity

What is unique about the stress-response paradigm?

- Stressors and outcomes are identified
- Longitudinal with repeated measures
- Person-centered
- Informs a unique class of interventions
- **Prevention-oriented**

What is unique about the stress-response paradigm?

- Stressors and outcomes are identified
- Longitudinal with repeated measures
- Person-centered
- Informs a unique class of interventions
- Prevention-oriented

Bruce S. McEwen, Ph.D. (1938-2020)

ALFRED E. MIRSKY PROFESSOR

IMMUNOLOGY, VIROLOGY, AND MICROBIOLOGY | MECHANISMS OF HUMAN DISEASE |
NEUROSCIENCES AND BEHAVIOR | STEM CELLS, DEVELOPMENT, REGENERATION, AND AGING

Studies the molecular mechanisms underlying the effects of stress and sex hormones on the brain.



HAROLD AND MARGARET MILLIKEN HATCH LABORATORY OF NEUROENDOCRINOLOGY →



Thank you

Resiliencies at the NIA: *A Collection of Multiple Tales ...*

Giovanna Zappalà, Ph.D, M.P.H.

National Institute on Aging



Conceptual Framework for Resiliencies

Individual Moderators (Resilience Resources)

- Age
- Health Status
- Lifestyle
- Cognitive ability
- Socioemotional skills
- Social relationships
- Environmental Factors
 - Physical
 - Social
 - Biological




Stressors

- Infection
- Chemotherapy
- Early Life Adversity
- Acute or chronic psychological stress
- Alzheimer's neuropathology



Outcome



Outcomes

- ❖ Wound healing
- ❖ Survival
- ❖ Functional status
- ❖ Psychological well-being
- ❖ Cognitive function

Time



Physical and/or Behavioral Resiliencies



National Institute on Aging

Developing a Test for Resilience


Resilience defined as “*the capacity of every cell in an organism to respond to physical or chemical stresses, irrespective of cognitive involvement*”

- ❑ **Develop functional resilience tests** to assess in young and middle-aged animals their overall ability to cope with physical and molecular stresses that mimic those encountered by human subjects
- ❑ Select platforms that allow **stratification among non-responders, normal responders and robust responders** and assess whether they are predictive of lifespan and health span
- ❑ **Validate** these platforms against interventions already known to improve lifespan and/or health span

Division of Aging Biology




Interventions that Extend Lifespan May do so by Improving Healthspan



An Integrative Science Approach to Resilience: The Notre Dame Study of Health & Well-being (UH3AG057039; Cindy Bergeman, PI)



UNIVERSITY OF
NOTRE DAME




Division of Behavioral and Social Research



Study finds support for System Integrity Perspective: **Associations Between Brain Age and Cognitive Function are Present Since Childhood**

A) Cognitive Function



Elliott et al., (2019). *Mol Psych.*



Predictors and Determinants of Age-Related Changes in Physiologic Resiliencies to Physical Stressors in Humans: **a Paradigm to Develop Novel Interventions**

- ❑ **Gap in knowledge** in our understanding of **age-related changes** in responses **to physical stressors**
- ❑ Understanding resiliencies may offer **better predictive value** for short- and long-term health outcomes **than static measures** of function or indicators of disease
- ❑ Insight into **changes in resiliencies across the lifespan** could reveal **aging mechanisms** underlying decrements in function and **factors contributing to the maintenance of healthy aging phenotypes**
- ❑ The availability of **clinical tests of resiliencies** could improve clinical management of older patients -- *Effective Resilience Test*:
 - Well-defined, **quantifiable** stressor;
 - Reliably **measurable outcome** of interest **prior to**, and at multiple time points **after**, application of the stressor;
 - **Good predictive value** for short- and long-term clinical outcomes


Division of Geriatrics and Clinical Gerontology



Focus on Potential Strategies **to Increase Resiliencies**



Hormesis and the concept of **Eustressors** ... *Enhancing Resiliencies through Mild Stressors—a Primary Prevention Paradigm*



NIA Resilience-AD Program

RFA-AG-17-061

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s) National Institutes of Health (NIH)

Components of Participating Organizations National Institute on Aging (NIA)

Funding Opportunity Title Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's Disease Risk (R01)

This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimer's disease.

RFA-AG-18-029

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s) National Institutes of Health (NIH)

Components of Participating Organizations National Institute on Aging (NIA)

Funding Opportunity Title Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's Disease Risk (R01 - Clinical Trial Not Allowed)

Division of Neuroscience



RFA-AG-18-024

Department of Health and Human Services Part 1. Overview Information

Participating Organization(s) National Institutes of Health (NIH)

Components of Participating Organizations National Institute on Aging (NIA)

Funding Opportunity Title Collaboratory on Research Definitions for Cognitive Reserve and Resilience to Alzheimer's Disease (R24 Clinical Trial Not Allowed)

RFA-AG-21-015

Department of Health and Human Services Part 1. Overview Information

Participating Organization(s) National Institutes of Health (NIH)


Components of Participating Organizations National Institute on Aging (NIA)

Funding Opportunity Title Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age (U19 Clinical Trial Not Allowed)

STARRRS

Successful Trajectories of Aging: Reserve and Resilience in RatS

\$7.4M project through NIA's IRP. Longitudinal observations (over lifespan) to examine cell biological, behavioral, and other factors that mediate and predict successful brain and cognitive aging, and ultimately for testing interventions aimed at optimally positive aging trajectories. Will create open-source data and a sample hub to be shared with the entire aging science community.



COLLABORATORY ON RESEARCH DEFINITIONS FOR RESERVE AND RESILIENCE IN COGNITIVE AGING AND DEMENTIA

Research opportunities and Needs for the development of **Cell-based Assays** to study Resiliencies

- ❑ Provide insight into **aging mechanisms** underlying decrements, as well as **protective factors** contributing to resilient phenotypes
- ❑ Facilitate comparison of research findings in pre-clinical models and in humans to identify potential **common mechanisms**
- ❑ Accelerate research progress of novel **therapeutic targets/interventions** to **enhance resiliencies**
- ❑ Validation of assays developed as research tools for use as **new clinical diagnostics**
- ❑ Examples:
 - Leverage/adapt existing cell-based methods
 - Use of patient's circulating stem/progenitor cells and co-cultures
 - Simultaneous measurements of different cellular functions



❑ **Division of Aging Biology**

- Felipe Sierra, Ph.D.
- Francesca Macchiarini, M.S., Ph.D.

❑ **Division of Behavioral and Social Research**

- Lis Nielsen, Ph.D.
- Dana Plude, Ph.D.
- Jonathan King, Ph.D.

❑ **Division of Geriatrics and Clinical Gerontology**

- Evan Hadley, M.D.
- Basil Eldadah, M.D., Ph.D.
- Chhanda Dutta, Ph.D.
- Giovanna Zappalà, Ph.D., M.P.H.

❑ **Division of Neuroscience**

- Eliezer Masliah, M.D.
- Molly Wagster, Ph.D.
- Coryse St. Hillaire-Clarke, Ph.D.
- Suzana Petanceska, Ph.D.



RCCN Webinar

Resilience and Reserve: Defining, Refining, and Advancing Research in Aging

Suzana Petanceska PhD
Division of Neuroscience



NIA Division of Neuroscience


Understanding all Aspects of Cognitive Resilience at All Levels of Biologic Complexity

- [PAR-17-054](#): Leveraging Existing Cohort Studies to Clarify Risk and Protective Factors for Alzheimer's Disease and Related Dementias (R01)
- [PAR-17-047](#) / [PAR-18-706](#) / [*PAR-19-070 - NOT-AG-19-033](#): Selective Cell and Network Vulnerability in Aging and Alzheimer's Disease (R01)
- [RFA-AG-17-061](#) / [RFA-AG-18-029](#): Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's Disease Risk (R01)
- [RFA-AG-18-024](#): Collaboratory on Research Definitions for Cognitive Reserve and Resilience to Alzheimer's Disease (R24)
- [RFA-AG-19-025](#) / [RFA-AG-19-026](#): Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R43/R44)/(R41/42)
- [*RFA-AG-21-015](#): Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age (U19)

NIA Program Directors: Dallas Anderson, Marilyn Miller, Brad Wise, Molly Wagster, Jonathan King, [Suzana Petanceska](#)

*Active Funding Opportunities

**NIH AD Research Summits:
Path to Treatment and Prevention**



May 14-15, 2012
Feb 9-10, 2015
March 1-2, 2018

**Cognitive
Aging**

SUMMIT III

Resilience & Reserve
April 6-7, 2017




NIH AD Research Summits: Overarching Recommendations

- Recognize the **heterogeneity and the multifactorial nature** of the disease.
- Understand all aspects of healthy aging and resilience to AD to inform new prevention strategies.**
- Support extensive molecular of existing and establish new cohorts to **fill the gaps in large-scale human data** needed to **build predictive models** of disease and wellness.
- Employ **data-driven research paradigms** such as systems biology and systems pharmacology.
- Enable **rapid and extensive sharing** of data, disease models, and biological specimens.
- Develop **computational tools and infrastructure** for storage, integration, and analysis of large-scale biological and other patient-relevant data.
- Build **new multidisciplinary translational teams** and create virtual and real spaces where these teams can operate.
- Support and enable **open science**.
- Change** academic, publishing, and funding **incentives** to promote collaborative, transparent, and reproducible research.
- Engage **patients, caregivers** and citizens **as direct partners in research**.

RFA-AG-17-061 / RFA-AG-18-029: Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s Disease Risk (R01)

- ❑ Gain deeper understanding of the molecular mechanisms by which gene-environment interactions lead to cognitively resilient phenotypes, through integrative network analysis of multi-omic data collected from individuals resilient to various types of AD risk*.
- ❑ Identify and experimentally validate molecular drivers of cognitive resilience that may serve as novel therapeutic targets for AD prevention.





*HIGH AD RISK: E4 homozygous, Down Syndrome individuals, FAD mutation carriers, very old age (90+, centenarians), presence of pathologic lesions (amyloid, tau).


RESILIENCE-AD Program: Learning from the outliers to identify new targets for AD prevention

R56	AG061837-01	LEE, JOSEPH HYUNGWOO (contact); KRINSKY-MCHALE, SHARON J	Identification of protective factors for cognitive resilience in adults with Down Syndrome: A multi-omic study
R01	AG057907-03	ZHANG, BIN (contact); EHRLICH, MICHELLE E; HAROUTUNIAN, VAHRAM	Integrative Network Modeling of Cognitive Resilience to Alzheimers Disease
R01	AG057909-04	BARZILAI, NIR J (contact); ZHANG, ZHENG DONG D	Resilience to Alzheimers disease in humans with exceptional longevity
R01	AG057911-03	GAITERI, CHRISTOPHER A	Identifying the molecular systems, networks, and key molecules that underlie cognitive resilience
R01	AG057912-03	LEVINE, MORGAN ELYSE (contact); HORVATH, STEVE	Molecular Networks Underlying Resilience to Alzheimers Disease Among APOE E4 Carriers
R01	AG057914-03	KACZOROWSKI, CATHERINE COOK	Systems Genetics Analysis of Resilience to Alzheimer's disease
R01	AG057915-03	BENDALL, SEAN CURTIS (contact); ANGELO, ROBERT MICHAEL; MONTINE, THOMAS J	MIRIAD - Multiplexed Imaging of Resilience In Alzheimers Disease
R01	AG061796-02	ERTEKIN-TANER, NILUFER	Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD
R01	AG061798-02	GAITERI, CHRISTOPHER A	Identifying the origins of resilience through human single cell molecular networks, then testing them in diverse, resilient, human IPS lines
R01	AG061800-02	HERSKOWITZ, JEREMY HARTFORD (contact); GAITERI, CHRISTOPHER A; SEYFRIED, NICHOLAS THOMAS	Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease

Harnessing the Power of Big Data and Open Science to Understand the Complex Biology of Disease Risk and Resilience and Discover New Therapeutic Targets and Biomarkers




M²OVE-AD – Molecular Mechanisms of the Vascular Etiology of AD
Psych-AD - Molecular Mechanisms of the Neuropsychiatric Symptoms in AD



<https://adknowledgeportal.synapse.org>

AD Knowledge Portal – Data, Research tools, Collaborators



17,053 biosamples | 15 genomic data types | 7,261 human donors

Accessing Data From Individual Studies



STUDY

The AD-BXD Study

Jax

C57BL/6J mice hemizygous for the dominant 5XFAD transgene were bred with genetically diverse recombinant inbred strains from the BXD genetic reference panel. The F1 progeny each harbor one maternally derived B allele and either a B or D paternally derived allele at any given genomic locus.

Data Types	Behavior Process, Gene Expression, Immunoassay, Metadata
Diagnosis	5XFAD, WT
Tissue	Hippocampus
Species	Mouse
Program	Resilience-AD
Grant	R01AG057914

Study Description
Access Requirements
Methods
Study Metadata
Study Data
Data Updates

STUDY DESCRIPTION

The AD-BXD study

In this study, the authors develop and characterize the first genetically diverse mouse model of aging and Alzheimer's disease. Female congenic C57BL/6J mice hemizygous for the dominant 5XFAD transgene (Oakley et al., 2006), which consists of 5 human mutations known to cause familial AD [three in amyloid precursor protein (APP; Swedish: K670N, M671L, Florida: I716V, and London: V717I) and two in presenilin 1 (PSEN1; M146L and L286V), were obtained from The Jackson Laboratory **JAX MMRRC Stock No: 34848-JAX**. These mice were bred with 28 males from a set of genetically diverse recombinant inbred strains from the well-established BXD genetic reference panel (Peirce et al., 2004). The F1 progeny resulting from this B6-5XFAD by BXD cross are isogenic recombinant inbred backcross mice, each harboring one maternally derived B allele and either a B or D paternally derived allele at any given genomic locus. As expected from a Mendelian pattern of inheritance, approximately 50% of these F1 mice carry the 5XFAD transgene (termed AD-BXDs) and approximately 50% are non-transgenic (Ntg) littermate controls referred to Ntg- BXDs. All mouse experiments occurred at University of Tennessee Health

Accessing Data Across Studies

Study 43648

Species 20699

Organ 3787

Data Type : geneExpression
20699 data files

geneExpression (43648) chromatinActivity (20699) behavior process (3787) analysis (2257) electrophysiology (2110) genomicVariants (1353)
proteomics (1098) metabolomics (126) image (109) tool (53) unannotated (44) clinical (43) immunoassay (39)
Pharmacokinetic Study (6) chromatinActivity (2) geneExpression,genomicVariants,chromatinActivity (1) demographic (1) Select All

Showing 43648 data files

Data Type	Assay	Study	tissue
geneExpression	rnaArray	HBTRC	dorsolateral prefrontal cortex
geneExpression	rnaArray	MSBB_ArrayTissuePanel	frontal pole
geneExpression	rnaArray	MSBB_ArrayTissuePanel	occipital visual cortex
geneExpression	rnaArray	MSBB_ArrayTissuePanel	inferior temporal gyrus
geneExpression	rnaArray	MSBB_ArrayTissuePanel	middle temporal gyrus

Accessing Tools - Computational

Tools


Computational

Diagnosis

Grant

Program

Software Type

Search 

Experimental +

Displaying 7 Computational Tools by Program

AMP-AD (7) [Select All](#)



TOOL

MEGENA Multiscale Clustering of Geometrical Network

Software package

Co-Expression Network Analysis by adopting network embedding technique.

CONTRIBUTOR Won-Min Song, Bin Zhang

PROGRAM AMP-AD

DOCUMENTATION <https://doi.org/10.1371/journal.pcbi.1004574>

Accessing Tools - Experimental

Computational +

Experimental

Diagnosis

Grant

Model Type


Program

Reagent Type

Search 🔍

Displaying 35 Experimental Tools by Reagent Type

Mouse Models (35) | Viral Vectors (1) | Drosophila Models (1) | Gene Expression Panels (1) | Select All



TOOL

5XFAD Mouse Model


Mouse Models

5XFAD transgenic mice overexpress both mutant human APP(695) with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) Familial Alzheimer's Disease (FAD) mutations and human PS1 harboring two FAD mutations, M146L and L286V. Expression of both transgenes is regulated by neural-specific elements of the mouse Thy1 promoter to drive overexpression in the brain. These 5XFAD transgenic mice rapidly ...[Show More](#)

DIAGNOSIS	Familial AD
MODEL TYPE	APP Models, PS1 Models
MODEL NAME	5XFAD

[Show More](#)

Agora: Sharing Analytical Results and Insights



Open-source platform providing curated, AMP-AD verified, systems biology analyses for any gene of interest.

Enables researchers at large to discover and evaluate the evidence behind the AMP-AD nominated targets as well as to nominate new targets.

542 unique targets currently available, derived from unbiased, computational analyses of high-dimensional human omic data.

<https://agora.ampadportal.org/>

Agora Targets – Systems Biology Evidence

VGf

VGf nerve growth factor inducible


NOMINATION DETAILS

SUMMARY


EVIDENCE

DRUGGABILITY



RNA



Protein



Metabolites



Druggability

Small Molecule Modality	13	Unknown: There is no information on ligands or structure in any of the categories above.	+
Antibody Modality	1	Secreted protein. Highly accessible to antibody-based therapies.	+
Safety	4	Probable safety risks requiring mitigation. More than two of: high off-target gene expression, cancer driver, essential gene, associated deleterious genetic disorder, HPO phenotype associated gene, or black box warning on clinically used drug.	-

NIA Resources to Support Resilience Related Research

Dana Plude, PhD

Division of Behavioral and Social Research

NIA

dana.plude@nih.gov

RCCN Webinar

April 30, 2020

OUTLINE

- Funding Opportunities
- Other Resources
- Opportunities to Shape Resilience Research

Funding Opportunities

• Funding Opportunity Announcements (FOAs)

- [PAR-16-326](#) Advancing Basic Behavioral and Social Research on Resilience: An Integrative Science Approach (UG3/UH3) - **EXPIRED**
- [RFA-AG-18-029](#) Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's Disease Risk (R01) - **EXPIRED**
- [PA-19-055](#) (R01 Parent R01 Clinical Trial Required)
- [PA-19-056](#) (R01 Parent R01 Clinical Trial Not Allowed)
- [PA-19-091](#) (R01 Basic Experimental Studies with Humans Required)

• Notices of Special Interest (NOSIs)

- [Extramural Nexus](#) – NOSIs express areas of focal interest to Institutes
- More expedient than FOAs
- NOSI 'points' to FOA – enter NOSI number in field 4B of SF424 application

Funding Opportunities

- **Funding Opportunity Announcements (FOAs)**

- [PAR-16-326](#) Advancing Basic Behavioral and Social Research on Resilience: An Integrative Science Approach (UG3/UH3) - **EXPIRED**
- [RFA-AG-17-061](#) Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's Disease Risk (R01) - **EXPIRED**
- [PA-19-055](#) (R01 Parent R01 Clinical Trial Required)
- [PA-19-056](#) (R01 Parent R01 Clinical Trial Not Allowed)
- [PA-19-091](#) (R01 Basic Experimental Studies with Humans Required)

- **Notices of Special Interest (NOSIs)**

- [Extramural Nexus](#) – NOSIs express areas of focal interest to Institutes
- More expedient than FOAs
- NOSI 'points' to FOA – enter NOSI number in field 4B of SF424 application

Funding Opportunities

- **Funding Opportunity Announcements (FOAs)**

- [PAR-16-326](#) Advancing Basic Behavioral and Social Research on Resilience: An Integrative Science Approach (UG3/UH3)
- [RFA-AG-17-061](#) Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's Disease Risk (R01)
- [PA-19-055](#) (R01 Parent R01 Clinical Trial Required)
- [PA-19-056](#) (R01 Parent R01 Clinical Trial Not Allowed)
- [PA-19-091](#) (R01 Basic Experimental Studies with Humans Required)

- **Notices of Special Interest (NOSIs)**

- [Extramural Nexus](#) – NOSIs express areas of focal interest to Institutes
- More expedient than FOAs
- NOSI 'points' to FOA – enter NOSI number in field 4B of SF424 application

NIH Guide [LISTSERV](#): Weekly E-Mail - New NIH Guide Postings

NIA Funding Opportunities

Funding Opportunity Title	Number	Open/Close	Category
<u>Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Related Dementias and Cognitive Resilience</u>	NOT-AG-18-053	12/17/2018 11/13/2021	Population Studies, Epidemiology
<u>New/Unconventional Animal Models of Alzheimer's Disease (R24 Clinical Trial Not Allowed)</u>	RFA-AG-21-003	1/13/2020 10/8/2020	Infrastructure
<u>Notice of Special Interest: Digital Technology for Early Detection of Alzheimer's Disease and Related Dementias</u>	NOT-AG-20-017	3/11/2020 11/13/2021	Biomarkers/ Diagnosis

NOSI Connection to FOA

Notice Number

Notice to Specify High-Priority Research Topic for PAR-19-070 and PAR-19-071

Notice Number: NOT-AG-18-053

Key Dates

Release Date: December 17, 2018

Related Announcements

[PAR-19-070](#)

[PAR-19-071](#)

Issued by

National Institute on Aging (NIA)

Purpose

This Notice of Information specifies a high-priority topic of interest for PAR-19-070 "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)" and PAR-19-071 "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)".

FOA Number



National Institute
on Aging

Other Funding Opportunities

- Career Development & Training Awards
 - K's, F's, T's
- Administrative Supplements
 - [PA-18-591](#) - Administrative Supplements to Existing NIH Grants and Cooperative Agreements
 - [PA-18-906](#) - Research Supplements to Promote Diversity in Health-Related Research

Other Resources

- Research Networks
 - [Reversibility Network](#) – seed funding
 - [Interdisciplinary Network on Rural Population Health and Aging](#) – pilot funding
 - [Stress Measurement Network](#) - consultations
- Research Centers
 - [Alzheimer's Disease Centers](#)
 - [Claude D. Pepper Older Americans Independence Centers \(OAICs\)](#)
 - [Nathan Shock Centers of Excellence in the Basic Biology of Aging](#)
 - [Resource Centers for Minority Aging Research \(RCMARs\)](#)
 - [Edward R. Roybal Centers for Translation Research in the Behavioral and Social Sciences of Aging](#)
 - [Centers on the Demography and Economics of Aging](#)
- Research Centers Collaborative Network ([RCCN](#))
 - Pilot study funding tied to individual workshops

Other Resources

- Research Networks
 - [Reversibility Network](#) – seed funding
 - [Interdisciplinary Network on Rural Population Health and Aging](#) – pilot funding
 - [Stress Measurement Network](#) - consultations
- Research Centers
 - [Alzheimer's Disease Centers](#)
 - [Claude D. Pepper Older Americans Independence Centers \(OAICs\)](#)
 - [Nathan Shock Centers of Excellence in the Basic Biology of Aging](#)
 - [Resource Centers for Minority Aging Research \(RCMARs\)](#)
 - [Edward R. Roybal Centers for Translation Research in the Behavioral and Social Sciences of Aging](#)
 - [Centers on the Demography and Economics of Aging](#)
- Research Centers Collaborative Network ([RCCN](#))
 - Pilot study funding tied to individual workshops

Other Resources

- Research Networks
 - Reversibility Network – seed funding
 - Interdisciplinary Network on Rural Population Health and Aging – pilot funding
 - Stress Measurement Network - consultations
- Research Centers
 - Alzheimer's Disease Centers
 - Claude D. Pepper Older Americans Independence Centers (OAICs)
 - Nathan Shock Centers of Excellence in the Basic Biology of Aging
 - Resource Centers for Minority Aging Research (RCMARs)
 - Edward R. Roybal Centers for Translation Research in the Behavioral and Social Sciences of Aging
 - Centers on the Demography and Economics of Aging
- Research Centers Collaborative Network ([RCCN](#))
 - Pilot study funding tied to individual workshops

Opportunities to Shape Resilience Research

- [STARRRS](#) Longitudinal Rat Resource – NIA Intra/Extramural Program
 - [NOT-AG-19-017](#) – Request for Information
- [Collaboratory on Research Definitions](#) – Resilience & Reserve
 - [Call for Pilot Projects](#) – due date June 15, 2020
 - Workshop #2 slated for Sept 14-15, 2020
- [RCCN Workshops](#)
 - Resilience & Reserve in Aging – Nov 12-13 2019
 - Resilience Webinar # 2 – tba (June?)

Thank you

Q&A



**RESEARCH CENTERS
COLLABORATIVE NETWORK**
of the National Institute on Aging, NIH

www.rccn-aging.org

Follow [rccnaging](https://twitter.com/rccnaging) on Twitter





**RESEARCH CENTERS
COLLABORATIVE NETWORK**
of the National Institute on Aging, NIH

Coming Soon!
**Webinar on Resilience and Reserve:
Biology of Aging and Translational
Research**

Date TBA

(Join the RCCN mailing list or follow @rccnaging on Twitter for updates)

THANK YOU
for joining us
&
for completing
our brief
SURVEY.

(Survey will appear when you exit the webinar.)